STOCK TITAN

[Form 4] Viemed Healthcare, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

On 08/22/2025 Viemed Healthcare director and General Counsel Jeremy Trahan experienced equity award activity tied to prior grants. 2,986 cash-settled phantom share units vested and were reported as a cash settlement and simultaneous disposition of the underlying shares at a per-share value of $7.31. 5,971 Restricted Stock Units vested and converted into common shares, with 1,634 of those shares withheld to satisfy tax withholding. The reporting person holds 25,503 common shares following these transactions.

Il 08/22/2025 il direttore e consulente legale di Viemed Healthcare, Jeremy Trahan, ha registrato movimenti relativi a precedenti assegnazioni di azioni. Sono maturate 2,986 unità phantom liquidate in contanti e segnalate come liquidazione in contanti e contemporanea cessione delle azioni sottostanti a un valore per azione di $7.31. Sono maturate 5,971 Restricted Stock Units e sono state convertite in azioni ordinarie, con 1,634 di quelle azioni trattenute per il pagamento delle imposte. Dopo queste operazioni la persona che segnala detiene 25,503 azioni ordinarie.

El 08/22/2025 el director y asesor jurídico de Viemed Healthcare, Jeremy Trahan, registró actividad relacionada con adjudicaciones de acciones previas. Vencieron 2,986 unidades phantom liquidadas en efectivo y se informaron como liquidación en efectivo y disposición simultánea de las acciones subyacentes a un valor por acción de $7.31. Vencieron 5,971 Restricted Stock Units y se convirtieron en acciones ordinarias, reteniéndose 1,634 de esas acciones para cubrir la retención de impuestos. Tras estas transacciones, la persona informante posee 25,503 acciones ordinarias.

08/22/2025에 Viemed Healthcare의 이사 겸 법무 책임자 Jeremy Trahan는 이전에 부여된 주식과 관련된 보상 활동을 보고했습니다. 2,986주의 현금 정산형 팬텀 주식 단위가 베스트되어 현금 정산 및 기초 주식의 동시에 처분된 것으로 보고되었으며, 주당 가치는 $7.31였습니다. 5,971개의 제한 주식 단위(Restricted Stock Units)가 베스트되어 보통주로 전환되었고, 그중 1,634주는 원천징수 세금 충당을 위해 보류되었습니다. 이러한 거래 이후 보고자는 25,503주의 보통주를 보유하고 있습니다.

Le 08/22/2025, Jeremy Trahan, directeur et conseiller juridique de Viemed Healthcare, a effectué des opérations liées à des attributions d'actions antérieures. 2,986 unités phantom réglées en espèces ont acquis droit et ont été déclarées comme un règlement en espèces et une cession simultanée des actions sous-jacentes à une valeur par action de $7.31. 5,971 Restricted Stock Units ont acquis droit et ont été converties en actions ordinaires, dont 1,634 ont été retenues pour couvrir la retenue d'impôt. À la suite de ces opérations, la personne déclarante détient 25,503 actions ordinaires.

Am 08/22/2025 verzeichnete Jeremy Trahan, Direktor und General Counsel von Viemed Healthcare, Aktivitäten im Zusammenhang mit früheren Aktienzuteilungen. 2,986 barabgewickelte Phantom-Aktieneinheiten sind fällig geworden und wurden als Barausgleich und gleichzeitige Veräußerung der zugrunde liegenden Aktien zu einem Kurs von $7.31 pro Aktie gemeldet. 5,971 Restricted Stock Units sind fällig geworden und in Stammaktien umgewandelt worden, wobei 1,634 dieser Aktien zur Deckung der Steuerabzüge einbehalten wurden. Nach diesen Transaktionen hält die meldende Person 25,503 Stammaktien.

Positive
  • Vesting executed as scheduled: 5,971 RSUs and 2,986 phantom units vested consistent with the grant terms.
  • Transparent disclosure: The Form 4 reports cash settlement value per share at $7.31 and tax-withholding shares, providing clear mechanics of the transactions.
Negative
  • Net reduction in held shares due to tax withholding: 1,634 vested RSU shares were withheld to satisfy tax obligations.
  • Cash settlement of phantom units reduces potential future upside: 2,986 units were settled for cash rather than converted into long-term-held shares.

Insights

TL;DR Routine executive equity vesting and tax withholding; limited market impact at reported sizes.

The Form 4 documents scheduled vesting events rather than open-market sales or discretionary purchases. The cash settlement of 2,986 phantom units at the closing price of $7.31 and the conversion of 5,971 RSUs into shares are internal compensation mechanics. The withholding of 1,634 shares for taxes reduces net share issuance to the reporting person but does not create new dilution beyond the plan terms. For investors this is information about insider compensation timing, not an operational development.

TL;DR Compensation plan mechanics executed as designed; disclosures are complete and transparent.

The filing shows vesting schedules from awards originally granted on 08/22/2022 and vesting in three equal annual installments. The reporter used the appropriate Form 4 mechanics to show cash settlement of phantom units and share withholding for taxes. These actions align with standard governance practice for equity-based compensation and the form discloses the price basis used for the cash settlement.

Il 08/22/2025 il direttore e consulente legale di Viemed Healthcare, Jeremy Trahan, ha registrato movimenti relativi a precedenti assegnazioni di azioni. Sono maturate 2,986 unità phantom liquidate in contanti e segnalate come liquidazione in contanti e contemporanea cessione delle azioni sottostanti a un valore per azione di $7.31. Sono maturate 5,971 Restricted Stock Units e sono state convertite in azioni ordinarie, con 1,634 di quelle azioni trattenute per il pagamento delle imposte. Dopo queste operazioni la persona che segnala detiene 25,503 azioni ordinarie.

El 08/22/2025 el director y asesor jurídico de Viemed Healthcare, Jeremy Trahan, registró actividad relacionada con adjudicaciones de acciones previas. Vencieron 2,986 unidades phantom liquidadas en efectivo y se informaron como liquidación en efectivo y disposición simultánea de las acciones subyacentes a un valor por acción de $7.31. Vencieron 5,971 Restricted Stock Units y se convirtieron en acciones ordinarias, reteniéndose 1,634 de esas acciones para cubrir la retención de impuestos. Tras estas transacciones, la persona informante posee 25,503 acciones ordinarias.

08/22/2025에 Viemed Healthcare의 이사 겸 법무 책임자 Jeremy Trahan는 이전에 부여된 주식과 관련된 보상 활동을 보고했습니다. 2,986주의 현금 정산형 팬텀 주식 단위가 베스트되어 현금 정산 및 기초 주식의 동시에 처분된 것으로 보고되었으며, 주당 가치는 $7.31였습니다. 5,971개의 제한 주식 단위(Restricted Stock Units)가 베스트되어 보통주로 전환되었고, 그중 1,634주는 원천징수 세금 충당을 위해 보류되었습니다. 이러한 거래 이후 보고자는 25,503주의 보통주를 보유하고 있습니다.

Le 08/22/2025, Jeremy Trahan, directeur et conseiller juridique de Viemed Healthcare, a effectué des opérations liées à des attributions d'actions antérieures. 2,986 unités phantom réglées en espèces ont acquis droit et ont été déclarées comme un règlement en espèces et une cession simultanée des actions sous-jacentes à une valeur par action de $7.31. 5,971 Restricted Stock Units ont acquis droit et ont été converties en actions ordinaires, dont 1,634 ont été retenues pour couvrir la retenue d'impôt. À la suite de ces opérations, la personne déclarante détient 25,503 actions ordinaires.

Am 08/22/2025 verzeichnete Jeremy Trahan, Direktor und General Counsel von Viemed Healthcare, Aktivitäten im Zusammenhang mit früheren Aktienzuteilungen. 2,986 barabgewickelte Phantom-Aktieneinheiten sind fällig geworden und wurden als Barausgleich und gleichzeitige Veräußerung der zugrunde liegenden Aktien zu einem Kurs von $7.31 pro Aktie gemeldet. 5,971 Restricted Stock Units sind fällig geworden und in Stammaktien umgewandelt worden, wobei 1,634 dieser Aktien zur Deckung der Steuerabzüge einbehalten wurden. Nach diesen Transaktionen hält die meldende Person 25,503 Stammaktien.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Trahan Jeremy

(Last) (First) (Middle)
625 E. KALISTE SALOOM RD.

(Street)
LAFAYETTE LA 70508

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
VIEMED HEALTHCARE, INC. [ VMD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
General Counsel
3. Date of Earliest Transaction (Month/Day/Year)
08/22/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 08/22/2025 M 2,986 A (1) 24,152 D
Common Shares 08/22/2025 D 2,986 D $7.31(1)(2) 21,166 D
Common Shares 08/22/2025 M 5,971 A (3) 27,137 D
Common Shares 08/22/2025 F 1,634(4) D $7.31(2) 25,503 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Phantom Share Units (1) 08/22/2025 M 2,986 (5) 08/22/2025 Common Shares 2,986 (1) 0 D
Restricted Stock Units (3) 08/22/2025 M 5,971 (6) 08/22/2025 Common Shares 5,971 $0 0 D
Explanation of Responses:
1. Represents vesting of cash-settled phantom shares granted under the Issuer's Phantom Share Unit Plan. Each phantom share is the economic equivalent of one Company common share. The settlement of the phantom shares for cash is reported on this Form 4 as a disposition of the phantom shares being settled in exchange for the acquisition of the underlying Company common shares, and a simultaneous disposition of the underlying Company common shares to the Company for cash.
2. Per share value is based on the market closing price of the common shares for August 22, 2025.
3. Each Restricted Stock Unit (RSU) represents a contingent right to receive one common share.
4. Shares that were withheld by the issuer to satisfy the reporting person's tax obligation resulting from the vesting of restricted stock units.
5. Represents an award granted on August 22, 2022 under the Issuer's Phantom Share Unit Plan which vested in three equal annual installments beginning on the first anniversary of the grant date.
6. Restricted Stock Units (RSUs) granted to reporting person on August 22, 2022, which vested in three equal annual installments beginning on the first anniversary of the grant date.
Remarks:
/s/ Jesse Bergeron, Attorney-in-Fact 08/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Jeremy Trahan report on Form 4 for VMD?

The filing reports vesting and settlement on 08/22/2025: 2,986 phantom share units were cash-settled and 5,971 RSUs vested, with 1,634 RSU shares withheld for taxes.

How was the cash settlement value determined?

The per-share value used for the cash settlement is reported as $7.31, based on the market closing price for August 22, 2025.

How many Viemed common shares does the reporting person own after these transactions?

Following the reported transactions the reporting person beneficially owns 25,503 common shares (direct ownership).

Were these transactions open-market trades or compensation vesting events?

These transactions reflect compensation vesting events: cash settlement of phantom units and vesting/conversion of RSUs; they are not open-market discretionary trades.

When were the original awards granted that vested on 08/22/2025?

The phantom share units and RSUs were granted on 08/22/2022 and vested in three equal annual installments beginning on the first anniversary of the grant date.
Viemed Healthcare Inc

NASDAQ:VMD

VMD Rankings

VMD Latest News

VMD Latest SEC Filings

VMD Stock Data

273.44M
33.65M
13.24%
70.32%
1.23%
Medical Devices
Services-misc Health & Allied Services, Nec
Link
United States
LAFAYETTE